Comparative Pharmacology
Head-to-head clinical analysis: SYNALGOS DC versus XTAMPZA ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNALGOS DC versus XTAMPZA ER.
SYNALGOS-DC vs XTAMPZA ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydrocodeine is a semisynthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception. Aspirin inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby providing analgesic and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia by reducing pain perception and increasing the efficacy of other analgesics.
Oxycodone is a full mu-opioid receptor agonist, producing analgesia, euphoria, and sedation. Xtampza ER utilizes DETERx technology to provide extended-release properties and resist tampering.
1-2 capsules orally every 4 hours as needed for pain; each capsule contains dihydrocodeine bitartrate 16 mg, acetaminophen 356.4 mg, and caffeine 30 mg. Maximum: 8 capsules per day.
Initial: 9 mg orally every 12 hours with food; titrate by 9 mg every 3-7 days as needed; maximum dose: 36 mg every 12 hours.
None Documented
None Documented
Dihydrocodeine: 3.5-4.5 hours; aspirin: 15-20 minutes; caffeine: 3-6 hours. Context: Dihydrocodeine half-life supports q4-6h dosing; aspirin short half-life limits analgesia duration.
3-4 hours for immediate-release morphine; 8-12 hours for extended-release formulation (XTAMPZA ER), allowing twice-daily dosing
Renal: ~90% (dihydrocodeine, as metabolites, primarily glucuronides); biliary/fecal: ~10%.
Primarily renal (70-90% as morphine-3-glucuronide, morphine-6-glucuronide, and free morphine); biliary/fecal (10-20%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic